Recipharm Karlskoga AB, specialized in the manufacture of semi-solid products, and Pharmanest AB, a Stockholm-based pharmaceutical company specializing in developing products for local pain relief in obstetrics and gynecology, are pleased to announce the formation of a new pharmaceutical manufacturing contract for SHACT. SHACT is a product based on an innovative formulation of lidocaine, an anesthetic, and a proprietary application device developed to simplify topical application in the cervix and uterus

Recipharma and Pharmanest have reached a milestone in their existing collaboration, and Pharmanest is now preparing its candidate SHACT for launch. Additionally, the companies have reached a long-term agreement for commercial manufacturing, with the product launch date to be announced later. Jointly, the two companies will offer commercial supply to any market that Pharmanest determine to enter for supply and sales of its first pharmaceutical product SHACT.

Source: Recipharm